Ginkgo biloba for intermittent claudication

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Nicolaï, Saskia P ^a   Kruidenier, L M ^b   Bendermacher, B L ^b   Prins, M H ^b   Teijink, J A ^b  

^a Zuyderland Medical Centre   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GINKGO BILOBA EXTRACT; PLACEBO;

ANKLE BRACHIAL INDEX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GINKGO BILOBA; HUMAN; INTERMITTENT CLAUDICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; WALKING;

EID: 44349102243     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006888     Document Type: Review

References (16)

1. ATC 2002 Antithrombotic Trialist's Collaboration (ATC). Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. British Medical Journal 2002;324:71-86.
2. Bendermacher 2005 Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Medical management of peripheral arterial disease. Journal of Thrombosis Haemostasis 2005;3(8):1628-37.
3. Bendermacher 2006 Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database of Systematic Reviews 2006, Issue 2.Art. No.: CD005263. DOI: 10.1002/14651858.CD005263.pub2.
4. Fontaine 1954 Fontaine VR, Kim M, Kieny R. Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripheren Durchblutungsstörungen]. Helvetica Chirurgica Acta 1954;5/6:499-533.
5. Fowkes 1991 Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: Prevalence of asymptomatic and symptomatic arterial disease in the general population. International Journal of Epidemiology 1991;20(2):384-92.
6. Hankey 2006 Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. The Journal of the American Medical Association 2006;295(5):547-53.
7. Hooi 1998 Hooi JD, Stoffers HE, Kester AD, Rinkens PE, Kaiser V, van Ree JW. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusion disease. The Limburg PAOD study. Scandinavian Journal of Primary Health Care 1998;16(3):177-82.
8. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
9. Kleijnen 1992 Kleijnen J, Knipschild P. Ginkgo biloba. The Lancet 1992;340:1136-9.
10. Korth 1988 Korth R, Nunez D, Bidault J, Benviste J. Comparison of three pafacether antagonist ginkgolides. European Journal of Pharmacology 1988;152(1-2):101-10.
11. Leng 2004 Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2004, Issue 1.Art. No.: CD000990. DOI:10.1002/14651858.CD000990.
12. Meijer 1998 Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the eldery: The Rotterdam Study. Arteriosclerosis, Thrombosis & Vascular Biology 1998;18(2): 185-92.
13. Murabito 2002 Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. American Heart Journal 2002;143(6):961-5.
14. Pincemail 1989 Pincemail J, Dupuis M, Nasr C, Hans P, Haag-Berrurier M, Anton R, et al.Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia 1989;45(8):708-12.
15. Robak 1988 Robak J, Gryglewski RJ. Flavonoids are scavengers of superoxide anions. Biochemical Pharmacology 1988;37(5):837-41.
16. Rutherford 1997 Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al.Recommended standards for reports dealing with lower extremity ischemia: revised version.[erratum appears in J Vasc Surg 2001 Apr;33(4):805]. Journal of Vascular Surgery 1997;26(3):517-38.